세계의 디지털 바이오마커 시장 : 유형별, 용도별, 진료 행위별, 최종 사용자별 - 기회 분석 및 산업 예측(2023-2032년)

According to a new report published by Allied Market Research, titled, "Digital Biomarkers Market," The digital biomarkers market was valued at $2.1 billion in 2022, and is estimated to reach $14.7 billion by 2032, growing at a CAGR of 21.3% from 2023 to 2032.

Digital biomarkers are characterized as measurable physiological and behavioral data that are obtained and assessed using digital devices such as portable, wearable, implantable, or ingestible ones. The information gathered is often used to forecast, affect, or explain outcomes connected to health. Digital biomarkers offer another chance to gather factual data that has therapeutic significance. This innovative open-access multidisciplinary approach unites informatics, engineering, biomedicine, regulatory science, and computer science.

The digital biomarkers market growth is driven by high presence of market players who manufacture digital biomarkers and increase in prevalence of chronic diseases such as cardiovascular diseases, respiratory diseases, psychiatric diseases, neurological diseases, and others. Digital biomarkers are used to monitor a wide range of diseases and health conditions. Digital biomarkers aim to monitor heart rate, heart rate variability, blood pressure, and other related parameters to assess the risk of cardiovascular diseases such as hypertension, arrhythmias, and heart failure. These biomarkers can be utilized to assess and monitor mental health conditions such as depression, anxiety, and bipolar disorder by analyzing patterns in sleep, activity levels, social interactions, and speech characteristics.

Moreover, digital biomarkers can aid in the monitoring and management of neurological conditions like Parkinson's disease, Alzheimer's disease, multiple sclerosis, and epilepsy. These biomarkers can include gait analysis, tremor frequency, cognitive performance, and sleep disturbances. Digital biomarkers can help track and analyze pain levels, activity patterns, sleep quality, and mood fluctuations in patients with chronic pain conditions, assisting in personalized pain management approaches.

For instance, according to the British Heart Foundation, in 2022, around 1,139,140 people were reported to have been suffering from heart and circulatory diseases in the UK. As per the same source, in 2022, around 650,681 male and 488,320 female population were suffering from heart and circulatory diseases in the UK. Thus, rise in number of chronic diseases is anticipated to drive the demand for digital biomarker and boost the growth of the market.

In addition, geriatric population is more susceptible to chronic diseases such as cardiovascular diseases, neurological disorders, respiratory diseases, and others. Thus, increase in the number of geriatric populations is expected to witness growth in prevalence of neurological diseases such as Alzheimer's dementia (AD). Therefore, this is expected to increase the demand for digital biomarkers and boost the growth of the market. According to World Health Organization, (WHO), population aged 60 years and over were expected to increase from 1 billion in 2020 to 1.4 billion in 2022 globally. By 2050, the global population of people aged 60 years and older is expected to increase by two-fold. The number of people aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

Moreover, according to Alzheimer's Association, in 2022, an estimated 6.5 million Americans aged 65 and older were reported to have been living with Alzheimer's dementia (AD). This number is projected to grow to 13.8 million by 2060. On the other hand, data privacy and security concerns, and lack of awareness is anticipated to hamper the growth of the market. However, increase in demand for digital medical devices in the developed countries such as U.S., Canada, and Germany and growth opportunities in emerging markets are expected to create immense opportunities for the digital biomarkers market during the forecast period.

The digital biomarkers market is segmented on the basis of type, application, end user and region. By type the market is divided into wearable, mobile application, software, and others (sensor, card, and implantable). By application, the market is classified into cardiovascular disease, sleep & movement disease, neurological disorders, and others. (respiratory diseases, diabetes, psychiatric and musculoskeletal disorders). By clinical practice, the market is classified into monitoring, diagnostic and prognostic. By end user, the market is divided into healthcare companies, hospitals, and others (payers and patients)

Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global digital biomarkers market are ActiGraph LLC, Verily Life Sciences, Alivecor, koneksahealth, Amgen, Brainomix, Feel Therapeutics, Sonde Health, Inc., Empatica, Clario. Key players operating in the market have adopted product approval, product launch, acquisition and agreement as their key strategies to expand their digital biomarkers market share.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the digital biomarkers market analysis from 2022 to 2032 to identify the prevailing digital biomarkers market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the digital biomarkers market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global digital biomarkers market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

• Product Benchmarking / Product specification and applications
• Upcoming/New Entrant by Regions
• New Product Development/ Product Matrix of Key Players
• Patient/epidemiology data at country, region, global level
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By Type

• Wearable
• Mobile Application
• Others

By Application

• Neurological Disorders
• Respiratory Disease
• Others
• Cardiovascular Disease
• Diabetes

By Clinical Practice

• Monitoring
• Diagnostic
• Prognostic

By End User

• Healthcare Providers
• Healthcare Consumers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • South Africa,
  • Saudi Arabia
  • Rest of LAMEA

Key Market Players:

• ActiGraph LLC
• AliveCor
• Amgen Inc.
• Brainomix
• Clario
• Empatica
• Feel Therapeutics
• Koneksahealth
• Sonde Health, Inc.
• Verily Life Sciences LLC

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rise in prevalence of chronic diseases
    • 3.4.1.2. Increase in number of geriatric populations
    • 3.4.1.3. Benefits associated with digital biomarkers

• 3.4.2. Restraints
  • 3.4.2.1. Data security issue

• 3.4.3. Opportunities
  • 3.4.3.1. Rise in number of product approvals and products launches by market players.
  • 3.4.3.2. High presence of market players

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: DIGITAL BIOMARKERS MARKET, BY TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Wearable
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Mobile Application
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Others
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: DIGITAL BIOMARKERS MARKET, BY APPLICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Cardiovascular Disease
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Diabetes
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Neurological Disorders
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Respiratory Disease
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country
• 5.6. Others
  • 5.6.1. Key market trends, growth factors and opportunities
  • 5.6.2. Market size and forecast, by region
  • 5.6.3. Market share analysis by country

CHAPTER 6: DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Monitoring
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Diagnostic
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Prognostic
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: DIGITAL BIOMARKERS MARKET, BY END USER

• 7.1. Overview
  • 7.1.1. Market size and forecast
• 7.2. Healthcare Providers
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by region
  • 7.2.3. Market share analysis by country
• 7.3. Healthcare Consumers
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by region
  • 7.3.3. Market share analysis by country
• 7.4. Others
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by region
  • 7.4.3. Market share analysis by country

CHAPTER 8: DIGITAL BIOMARKERS MARKET, BY REGION

• 8.1. Overview
  • 8.1.1. Market size and forecast By Region
• 8.2. North America
  • 8.2.1. Key trends and opportunities
  • 8.2.2. Market size and forecast, by Type
  • 8.2.3. Market size and forecast, by Application
  • 8.2.4. Market size and forecast, by Clinical Practice
  • 8.2.5. Market size and forecast, by End User
  • 8.2.6. Market size and forecast, by country
    • 8.2.6.1. U.S.
    • 8.2.6.1.1. Key market trends, growth factors and opportunities
    • 8.2.6.1.2. Market size and forecast, by Type
    • 8.2.6.1.3. Market size and forecast, by Application
    • 8.2.6.1.4. Market size and forecast, by Clinical Practice
    • 8.2.6.1.5. Market size and forecast, by End User
    • 8.2.6.2. Canada
    • 8.2.6.2.1. Key market trends, growth factors and opportunities
    • 8.2.6.2.2. Market size and forecast, by Type
    • 8.2.6.2.3. Market size and forecast, by Application
    • 8.2.6.2.4. Market size and forecast, by Clinical Practice
    • 8.2.6.2.5. Market size and forecast, by End User
    • 8.2.6.3. Mexico
    • 8.2.6.3.1. Key market trends, growth factors and opportunities
    • 8.2.6.3.2. Market size and forecast, by Type
    • 8.2.6.3.3. Market size and forecast, by Application
    • 8.2.6.3.4. Market size and forecast, by Clinical Practice
    • 8.2.6.3.5. Market size and forecast, by End User
• 8.3. Europe
  • 8.3.1. Key trends and opportunities
  • 8.3.2. Market size and forecast, by Type
  • 8.3.3. Market size and forecast, by Application
  • 8.3.4. Market size and forecast, by Clinical Practice
  • 8.3.5. Market size and forecast, by End User
  • 8.3.6. Market size and forecast, by country
    • 8.3.6.1. Germany
    • 8.3.6.1.1. Key market trends, growth factors and opportunities
    • 8.3.6.1.2. Market size and forecast, by Type
    • 8.3.6.1.3. Market size and forecast, by Application
    • 8.3.6.1.4. Market size and forecast, by Clinical Practice
    • 8.3.6.1.5. Market size and forecast, by End User
    • 8.3.6.2. France
    • 8.3.6.2.1. Key market trends, growth factors and opportunities
    • 8.3.6.2.2. Market size and forecast, by Type
    • 8.3.6.2.3. Market size and forecast, by Application
    • 8.3.6.2.4. Market size and forecast, by Clinical Practice
    • 8.3.6.2.5. Market size and forecast, by End User
    • 8.3.6.3. UK
    • 8.3.6.3.1. Key market trends, growth factors and opportunities
    • 8.3.6.3.2. Market size and forecast, by Type
    • 8.3.6.3.3. Market size and forecast, by Application
    • 8.3.6.3.4. Market size and forecast, by Clinical Practice
    • 8.3.6.3.5. Market size and forecast, by End User
    • 8.3.6.4. Italy
    • 8.3.6.4.1. Key market trends, growth factors and opportunities
    • 8.3.6.4.2. Market size and forecast, by Type
    • 8.3.6.4.3. Market size and forecast, by Application
    • 8.3.6.4.4. Market size and forecast, by Clinical Practice
    • 8.3.6.4.5. Market size and forecast, by End User
    • 8.3.6.5. Spain
    • 8.3.6.5.1. Key market trends, growth factors and opportunities
    • 8.3.6.5.2. Market size and forecast, by Type
    • 8.3.6.5.3. Market size and forecast, by Application
    • 8.3.6.5.4. Market size and forecast, by Clinical Practice
    • 8.3.6.5.5. Market size and forecast, by End User
    • 8.3.6.6. Rest of Europe
    • 8.3.6.6.1. Key market trends, growth factors and opportunities
    • 8.3.6.6.2. Market size and forecast, by Type
    • 8.3.6.6.3. Market size and forecast, by Application
    • 8.3.6.6.4. Market size and forecast, by Clinical Practice
    • 8.3.6.6.5. Market size and forecast, by End User
• 8.4. Asia-Pacific
  • 8.4.1. Key trends and opportunities
  • 8.4.2. Market size and forecast, by Type
  • 8.4.3. Market size and forecast, by Application
  • 8.4.4. Market size and forecast, by Clinical Practice
  • 8.4.5. Market size and forecast, by End User
  • 8.4.6. Market size and forecast, by country
    • 8.4.6.1. Japan
    • 8.4.6.1.1. Key market trends, growth factors and opportunities
    • 8.4.6.1.2. Market size and forecast, by Type
    • 8.4.6.1.3. Market size and forecast, by Application
    • 8.4.6.1.4. Market size and forecast, by Clinical Practice
    • 8.4.6.1.5. Market size and forecast, by End User
    • 8.4.6.2. China
    • 8.4.6.2.1. Key market trends, growth factors and opportunities
    • 8.4.6.2.2. Market size and forecast, by Type
    • 8.4.6.2.3. Market size and forecast, by Application
    • 8.4.6.2.4. Market size and forecast, by Clinical Practice
    • 8.4.6.2.5. Market size and forecast, by End User
    • 8.4.6.3. India
    • 8.4.6.3.1. Key market trends, growth factors and opportunities
    • 8.4.6.3.2. Market size and forecast, by Type
    • 8.4.6.3.3. Market size and forecast, by Application
    • 8.4.6.3.4. Market size and forecast, by Clinical Practice
    • 8.4.6.3.5. Market size and forecast, by End User
    • 8.4.6.4. Australia
    • 8.4.6.4.1. Key market trends, growth factors and opportunities
    • 8.4.6.4.2. Market size and forecast, by Type
    • 8.4.6.4.3. Market size and forecast, by Application
    • 8.4.6.4.4. Market size and forecast, by Clinical Practice
    • 8.4.6.4.5. Market size and forecast, by End User
    • 8.4.6.5. South Korea
    • 8.4.6.5.1. Key market trends, growth factors and opportunities
    • 8.4.6.5.2. Market size and forecast, by Type
    • 8.4.6.5.3. Market size and forecast, by Application
    • 8.4.6.5.4. Market size and forecast, by Clinical Practice
    • 8.4.6.5.5. Market size and forecast, by End User
    • 8.4.6.6. Rest of Asia-Pacific
    • 8.4.6.6.1. Key market trends, growth factors and opportunities
    • 8.4.6.6.2. Market size and forecast, by Type
    • 8.4.6.6.3. Market size and forecast, by Application
    • 8.4.6.6.4. Market size and forecast, by Clinical Practice
    • 8.4.6.6.5. Market size and forecast, by End User
• 8.5. LAMEA
  • 8.5.1. Key trends and opportunities
  • 8.5.2. Market size and forecast, by Type
  • 8.5.3. Market size and forecast, by Application
  • 8.5.4. Market size and forecast, by Clinical Practice
  • 8.5.5. Market size and forecast, by End User
  • 8.5.6. Market size and forecast, by country
    • 8.5.6.1. Brazil
    • 8.5.6.1.1. Key market trends, growth factors and opportunities
    • 8.5.6.1.2. Market size and forecast, by Type
    • 8.5.6.1.3. Market size and forecast, by Application
    • 8.5.6.1.4. Market size and forecast, by Clinical Practice
    • 8.5.6.1.5. Market size and forecast, by End User
    • 8.5.6.2. South Africa,
    • 8.5.6.2.1. Key market trends, growth factors and opportunities
    • 8.5.6.2.2. Market size and forecast, by Type
    • 8.5.6.2.3. Market size and forecast, by Application
    • 8.5.6.2.4. Market size and forecast, by Clinical Practice
    • 8.5.6.2.5. Market size and forecast, by End User
    • 8.5.6.3. Saudi Arabia
    • 8.5.6.3.1. Key market trends, growth factors and opportunities
    • 8.5.6.3.2. Market size and forecast, by Type
    • 8.5.6.3.3. Market size and forecast, by Application
    • 8.5.6.3.4. Market size and forecast, by Clinical Practice
    • 8.5.6.3.5. Market size and forecast, by End User
    • 8.5.6.4. Rest of LAMEA
    • 8.5.6.4.1. Key market trends, growth factors and opportunities
    • 8.5.6.4.2. Market size and forecast, by Type
    • 8.5.6.4.3. Market size and forecast, by Application
    • 8.5.6.4.4. Market size and forecast, by Clinical Practice
    • 8.5.6.4.5. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

• 9.1. Introduction
• 9.2. Top winning strategies
• 9.3. Product Mapping of Top 10 Player
• 9.4. Competitive Dashboard
• 9.5. Competitive Heatmap
• 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

• 10.1. ActiGraph LLC
  • 10.1.1. Company overview
  • 10.1.2. Key Executives
  • 10.1.3. Company snapshot
  • 10.1.4. Operating business segments
  • 10.1.5. Product portfolio
  • 10.1.6. Key strategic moves and developments
• 10.2. Verily Life Sciences LLC
  • 10.2.1. Company overview
  • 10.2.2. Key Executives
  • 10.2.3. Company snapshot
  • 10.2.4. Operating business segments
  • 10.2.5. Product portfolio
• 10.3. AliveCor
  • 10.3.1. Company overview
  • 10.3.2. Key Executives
  • 10.3.3. Company snapshot
  • 10.3.4. Operating business segments
  • 10.3.5. Product portfolio
  • 10.3.6. Key strategic moves and developments
• 10.4. Koneksahealth
  • 10.4.1. Company overview
  • 10.4.2. Key Executives
  • 10.4.3. Company snapshot
  • 10.4.4. Operating business segments
  • 10.4.5. Product portfolio
  • 10.4.6. Key strategic moves and developments
• 10.5. Amgen Inc.
  • 10.5.1. Company overview
  • 10.5.2. Key Executives
  • 10.5.3. Company snapshot
  • 10.5.4. Operating business segments
  • 10.5.5. Product portfolio
  • 10.5.6. Business performance
• 10.6. Empatica
  • 10.6.1. Company overview
  • 10.6.2. Key Executives
  • 10.6.3. Company snapshot
  • 10.6.4. Operating business segments
  • 10.6.5. Product portfolio
  • 10.6.6. Key strategic moves and developments
• 10.7. Sonde Health, Inc.
  • 10.7.1. Company overview
  • 10.7.2. Key Executives
  • 10.7.3. Company snapshot
  • 10.7.4. Operating business segments
  • 10.7.5. Product portfolio
• 10.8. Clario
  • 10.8.1. Company overview
  • 10.8.2. Key Executives
  • 10.8.3. Company snapshot
  • 10.8.4. Operating business segments
  • 10.8.5. Product portfolio
• 10.9. Feel Therapeutics
  • 10.9.1. Company overview
  • 10.9.2. Key Executives
  • 10.9.3. Company snapshot
  • 10.9.4. Operating business segments
  • 10.9.5. Product portfolio
  • 10.9.6. Key strategic moves and developments
• 10.10. Brainomix
  • 10.10.1. Company overview
  • 10.10.2. Key Executives
  • 10.10.3. Company snapshot
  • 10.10.4. Operating business segments
  • 10.10.5. Product portfolio